John Wiley & Sons B (WLYB) - Net Assets
Based on the latest financial reports, John Wiley & Sons B (WLYB) has net assets worth $848.24 Million USD as of April 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.59 Billion) and total liabilities ($1.74 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check WLYB PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $848.24 Million |
| % of Total Assets | 32.73% |
| Annual Growth Rate | 5.77% |
| 5-Year Change | -25.74% |
| 10-Year Change | -15.44% |
| Growth Volatility | 16.67 |
John Wiley & Sons B - Net Assets Trend (1986–2026)
This chart illustrates how John Wiley & Sons B's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see John Wiley & Sons B (WLYB) total market value.
Annual Net Assets for John Wiley & Sons B (1986–2026)
The table below shows the annual net assets of John Wiley & Sons B from 1986 to 2026. Also explore WLYB shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-04-30 | $848.24 Million | +12.77% |
| 2025-04-30 | $752.21 Million | +1.69% |
| 2024-04-30 | $739.72 Million | -29.22% |
| 2023-04-30 | $1.05 Billion | -8.51% |
| 2022-04-30 | $1.14 Billion | +4.67% |
| 2021-04-30 | $1.09 Billion | +16.89% |
| 2020-04-30 | $933.62 Million | -20.97% |
| 2019-04-30 | $1.18 Billion | -0.77% |
| 2018-04-30 | $1.19 Billion | +18.68% |
| 2017-04-30 | $1.00 Billion | -3.28% |
| 2016-04-30 | $1.04 Billion | -1.70% |
| 2015-04-30 | $1.06 Billion | -10.76% |
| 2014-04-30 | $1.18 Billion | +19.62% |
| 2013-04-30 | $988.36 Million | -2.87% |
| 2012-04-30 | $1.02 Billion | +4.06% |
| 2011-04-30 | $977.89 Million | +35.36% |
| 2010-04-30 | $722.44 Million | +40.68% |
| 2009-04-30 | $513.52 Million | -25.48% |
| 2008-04-30 | $689.12 Million | +30.14% |
| 2007-04-30 | $529.51 Million | +31.77% |
| 2006-04-30 | $401.84 Million | +1.33% |
| 2005-04-30 | $396.57 Million | -4.45% |
| 2004-04-30 | $415.06 Million | +20.66% |
| 2003-04-30 | $344.00 Million | +24.35% |
| 2002-04-30 | $276.65 Million | +25.74% |
| 2001-04-30 | $220.02 Million | +27.37% |
| 2000-04-30 | $172.74 Million | +6.50% |
| 1999-04-30 | $162.20 Million | +0.87% |
| 1998-04-30 | $160.80 Million | +24.65% |
| 1997-04-30 | $129.00 Million | +9.32% |
| 1996-04-30 | $118.00 Million | +19.43% |
| 1995-04-30 | $98.80 Million | +20.05% |
| 1994-04-30 | $82.30 Million | +15.43% |
| 1993-04-30 | $71.30 Million | +2.44% |
| 1992-04-30 | $69.60 Million | -26.66% |
| 1991-04-30 | $94.90 Million | +1.39% |
| 1990-04-30 | $93.60 Million | -1.27% |
| 1989-04-30 | $94.80 Million | -0.32% |
| 1988-04-30 | $95.10 Million | +3.03% |
| 1987-04-30 | $92.30 Million | +2.56% |
| 1986-04-30 | $90.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to John Wiley & Sons B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2529.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (April 2026)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.74 Billion | 204.91% |
| Common Stock | $83.18 Million | 9.81% |
| Other Comprehensive Income | $-442.22 Million | -52.13% |
| Total Equity | $848.24 Million | 100.00% |
John Wiley & Sons B Competitors by Market Cap
The table below lists competitors of John Wiley & Sons B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SoluM Co Ltd
KO:248070
|
$408.94 Million |
|
Cross Country Healthcare Inc
NASDAQ:CCRN
|
$409.00 Million |
|
Kaimei Electronic Corp
TW:2375
|
$409.15 Million |
|
TIDEWATER RENEWABLES LTD
F:7GZ
|
$409.20 Million |
|
Jiangsu Hualv Biological Technology Co.Ltd.
SHE:300970
|
$408.78 Million |
|
Stewards Inc.
NASDAQ:SWRD
|
$408.72 Million |
|
Angel Oak Financial Strategies Income Term Trust
NYSE:FINS
|
$408.69 Million |
|
Shanghai Kai Kai Industry Co Ltd A
SHG:600272
|
$408.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in John Wiley & Sons B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 752,206,000 to 848,242,000, a change of 96,036,000 (12.8%).
- Net income of 221,617,000 contributed positively to equity growth.
- Dividend payments of 74,358,000 reduced retained earnings.
- Share repurchases of 100,082,000 reduced equity.
- Other comprehensive income increased equity by 36,702,000.
- Other factors increased equity by 12,157,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $221.62 Million | +26.13% |
| Dividends Paid | $74.36 Million | -8.77% |
| Share Repurchases | $100.08 Million | -11.8% |
| Other Comprehensive Income | $36.70 Million | +4.33% |
| Other Changes | $12.16 Million | +1.43% |
| Total Change | $- | 12.77% |
Book Value vs Market Value Analysis
This analysis compares John Wiley & Sons B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.93x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 32.85x to 2.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1986-04-30 | $1.42 | $46.68 | x |
| 1987-04-30 | $1.48 | $46.68 | x |
| 1988-04-30 | $1.42 | $46.68 | x |
| 1989-04-30 | $1.39 | $46.68 | x |
| 1990-04-30 | $1.39 | $46.68 | x |
| 1991-04-30 | $1.62 | $46.68 | x |
| 1992-04-30 | $1.12 | $46.68 | x |
| 1993-04-30 | $1.20 | $46.68 | x |
| 1994-04-30 | $1.29 | $46.68 | x |
| 1995-04-30 | $1.51 | $46.68 | x |
| 1996-04-30 | $1.82 | $46.68 | x |
| 1997-04-30 | $1.97 | $46.68 | x |
| 1998-04-30 | $2.42 | $46.68 | x |
| 1999-04-30 | $2.45 | $46.68 | x |
| 2000-04-30 | $2.67 | $46.68 | x |
| 2001-04-30 | $3.47 | $46.68 | x |
| 2002-04-30 | $4.39 | $46.68 | x |
| 2003-04-30 | $5.44 | $46.68 | x |
| 2004-04-30 | $6.56 | $46.68 | x |
| 2005-04-30 | $6.39 | $46.68 | x |
| 2006-04-30 | $6.72 | $46.68 | x |
| 2007-04-30 | $9.08 | $46.68 | x |
| 2008-04-30 | $11.62 | $46.68 | x |
| 2009-04-30 | $8.61 | $46.68 | x |
| 2010-04-30 | $12.11 | $46.68 | x |
| 2011-04-30 | $15.94 | $46.68 | x |
| 2012-04-30 | $16.61 | $46.68 | x |
| 2013-04-30 | $16.41 | $46.68 | x |
| 2014-04-30 | $19.87 | $46.68 | x |
| 2015-04-30 | $17.70 | $46.68 | x |
| 2016-04-30 | $17.66 | $46.68 | x |
| 2017-04-30 | $17.24 | $46.68 | x |
| 2018-04-30 | $20.57 | $46.68 | x |
| 2019-04-30 | $20.42 | $46.68 | x |
| 2020-04-30 | $16.61 | $46.68 | x |
| 2021-04-30 | $19.33 | $46.68 | x |
| 2022-04-30 | $20.18 | $46.68 | x |
| 2023-04-30 | $18.54 | $46.68 | x |
| 2024-04-30 | $13.46 | $46.68 | x |
| 2025-04-30 | $13.72 | $46.68 | x |
| 2026-04-30 | $15.93 | $46.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently John Wiley & Sons B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 26.13%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.22%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 3.06x
- Recent ROE (26.13%) is above the historical average (14.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1986 | 8.44% | 3.56% | 1.13x | 2.11x | $-1.40 Million |
| 1987 | 5.42% | 2.19% | 1.17x | 2.12x | $-4.23 Million |
| 1988 | 4.94% | 1.96% | 1.15x | 2.19x | $-4.81 Million |
| 1989 | 4.32% | 1.58% | 1.36x | 2.01x | $-5.38 Million |
| 1990 | 2.88% | 0.96% | 1.13x | 2.66x | $-6.66 Million |
| 1991 | 4.32% | 1.73% | 0.94x | 2.65x | $-5.39 Million |
| 1992 | 4.45% | 1.25% | 1.16x | 3.07x | $-3.86 Million |
| 1993 | 10.80% | 2.82% | 1.24x | 3.09x | $570.00K |
| 1994 | 14.70% | 4.11% | 1.21x | 2.96x | $3.87 Million |
| 1995 | 18.52% | 5.53% | 1.34x | 2.51x | $8.42 Million |
| 1996 | 20.93% | 6.81% | 1.27x | 2.41x | $12.90 Million |
| 1997 | 15.74% | 4.70% | 0.94x | 3.55x | $7.40 Million |
| 1998 | 22.76% | 7.84% | 0.92x | 3.15x | $20.52 Million |
| 1999 | 24.48% | 7.81% | 0.96x | 3.26x | $23.48 Million |
| 2000 | 30.33% | 8.81% | 1.04x | 3.30x | $35.11 Million |
| 2001 | 26.78% | 9.60% | 1.04x | 2.67x | $36.92 Million |
| 2002 | 20.72% | 7.80% | 0.82x | 3.24x | $29.65 Million |
| 2003 | 25.37% | 10.22% | 0.89x | 2.78x | $52.87 Million |
| 2004 | 21.40% | 9.63% | 0.91x | 2.44x | $47.33 Million |
| 2005 | 21.14% | 8.61% | 0.94x | 2.60x | $44.18 Million |
| 2006 | 27.46% | 10.57% | 1.02x | 2.55x | $70.14 Million |
| 2007 | 18.81% | 8.07% | 0.49x | 4.78x | $46.67 Million |
| 2008 | 21.41% | 8.81% | 0.65x | 3.76x | $78.62 Million |
| 2009 | 24.98% | 7.96% | 0.72x | 4.33x | $76.91 Million |
| 2010 | 19.87% | 8.45% | 0.73x | 3.21x | $71.30 Million |
| 2011 | 17.58% | 9.86% | 0.72x | 2.49x | $74.10 Million |
| 2012 | 20.91% | 11.93% | 0.70x | 2.49x | $110.99 Million |
| 2013 | 14.59% | 8.19% | 0.63x | 2.84x | $45.39 Million |
| 2014 | 13.58% | 9.04% | 0.58x | 2.60x | $42.29 Million |
| 2015 | 16.76% | 9.71% | 0.61x | 2.85x | $71.36 Million |
| 2016 | 14.06% | 8.44% | 0.59x | 2.82x | $42.07 Million |
| 2017 | 11.33% | 6.61% | 0.66x | 2.60x | $13.33 Million |
| 2018 | 16.14% | 10.70% | 0.63x | 2.38x | $73.13 Million |
| 2019 | 14.24% | 9.35% | 0.61x | 2.49x | $50.13 Million |
| 2020 | -7.96% | -4.06% | 0.58x | 3.39x | $-167.65 Million |
| 2021 | 13.59% | 7.64% | 0.56x | 3.16x | $39.13 Million |
| 2022 | 12.98% | 7.12% | 0.62x | 2.94x | $34.08 Million |
| 2023 | 1.65% | 0.85% | 0.65x | 2.97x | $-87.27 Million |
| 2024 | -27.08% | -10.70% | 0.69x | 3.68x | $-274.29 Million |
| 2025 | 11.19% | 5.02% | 0.62x | 3.58x | $8.94 Million |
| 2026 | 26.13% | 13.22% | 0.65x | 3.06x | $136.79 Million |
Industry Comparison
This section compares John Wiley & Sons B's net assets metrics with peer companies in the Publishing industry.
Industry Context
- Industry: Publishing
- Average net assets among peers: $452,627,927
- Average return on equity (ROE) among peers: 6.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| John Wiley & Sons B (WLYB) | $848.24 Million | 8.44% | 2.06x | $408.88 Million |
| Dallasnews Corp (DALN) | $70.59 Million | -7.70% | 1.02x | $78.24 Million |
| Educational Development Corporation (EDUC) | $5.30 Million | 22.64% | 0.83x | $11.17 Million |
| Gannett Co Inc (GCI) | $295.37 Million | -26.41% | 7.10x | $298.63 Million |
| Lee Enterprises Incorporated (LEE) | $319.40 Million | 20.10% | 1.04x | $162.95 Million |
| New York Times Company (NYT) | $1.48 Billion | 20.40% | 1.56x | $10.45 Billion |
| Scholastic Corporation (SCHL) | $288.60 Million | 11.05% | 1.33x | $855.32 Million |
| TNL Mediagene Ordinary Shares (TNMG) | $-24.14 Million | 0.00% | 0.00x | $1.56 Million |
| John Wiley & Sons (WLY) | $1.18 Billion | 13.58% | 1.60x | $2.05 Billion |
About John Wiley & Sons B
John Wiley & Sons, Inc., a publisher, provides authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning in the United States, the United Kingdom, Germany, and internationally. It operates through Research and Learning segment. The company's Research segment provides scientific, technical, medical, and scholarly journals, as well as rela… Read more